Low-Cost, Commercial Scale Production of Sofosbuvir

Loading...
Thumbnail Image
Penn collection
Senior Design Reports (CBE)
Degree type
Discipline
Subject
sofosbuvir
hepatitis C
liver
drug production 6
Biochemical and Biomolecular Engineering
Chemical Engineering
Engineering
Funder
Grant number
License
Copyright date
Distributor
Related resources
Author
Solomon, Joseph
Hsu, Jake
Tong, Cynthia
Bliss, Ryan
Contributor
Abstract

Recent advances in antiviral therapeutics have produced highly effective small molecule drugs to treat Hepatitis C, a deadly infection of the liver. Sofosbuvir, a hepatitis C drug developed by Gilead Sciences, is a breakthrough treatment due to its low side effects and high cure rate. However, the cost of treatment is extraordinarily high, priced at $84,000 per treatment in the US. In response to backlash regarding the cost barriers in developing countries, Gilead has reached licensing agreements with generic pharmaceutical companies to produce the drug for markets in low-income countries such as India, Kenya, and Cuba among others. The report describes a cost-effective, commercial scale process design for the production of sofosbuvir. The proposed production facility is designed to deliver 350,000 kg/year of the active pharmaceutical ingredient, enough to treat 10 million patients per year. The production will be completed over one hundred batches, requiring operation of 120 days/year. Assuming an 11-year period of operation, detailed economic analysis suggests that this is a profitable venture with an IRR of 67.7% and a NPV of $1.2 billion USD.

Advisor
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Publication date
2017-04-18
Volume number
Issue number
Publisher
Publisher DOI
Journal Issue
Comments
Recommended citation
Collection